Glutathione: An Endogenous Antioxidant Tripeptide for Oxidative Stress and Skin Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to intravenous or compounded glutathione. Oral glutathione is a dietary supplement, not an FDA-approved drug. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Every cell in your body produces it. Every organ depends on it. And yet most standard blood panels never measure it. Glutathione is the most abundant intracellular antioxidant in human physiology, a tripeptide assembled from three amino acids: gamma-glutamate, cysteine, and glycine. It sits at the intersection of detoxification, immune regulation, and redox balance, and its levels decline with age in a pattern that researchers have increasingly linked to accelerated biological aging and disease vulnerability.

That combination of ubiquity, importance, and measurability has made glutathione one of the most commercially promoted and scientifically complicated compounds in the wellness space. The research base is genuinely deep, but the claims made about supplements often outrun what the evidence supports. This article covers what glutathione is, how it works, how delivery forms compare in practice, what the science shows about its use in skin lightening, and which biomarkers reflect its status in the body.

Key Takeaways

• Regulatory Status: Oral glutathione is an over-the-counter dietary supplement in the United States, not FDA-approved as a drug. Intravenous (IV) glutathione is a compounded product, not FDA-approved as a drug for any indication. As of April 2026, it is not classified as a bulk drug substance under Category 2 or Category 3 by the FDA.
• Research Stage: Extensive biochemical and preclinical research; growing body of human RCT data for oral and liposomal forms; IV evidence limited by small trial sizes and route-of-administration complexity; skin-lightening evidence inconclusive.
• Availability: Oral glutathione is widely available as a dietary supplement. IV glutathione is available through compounding pharmacies; Superpower does not offer or facilitate access to IV glutathione formulations.
• What it is: A tripeptide (γ-glutamyl-cysteinyl-glycine) and the body's primary intracellular antioxidant, synthesized endogenously in all cells.
• What the evidence actually shows: Oral supplementation can meaningfully raise body GSH stores at 500–1,000 mg/day over several months; precursor supplementation (GlyNAC) corrects GSH deficiency in older adults with additional metabolic benefits; skin-lightening evidence is limited and contested; IV data remains preliminary.
• Authoritative reference: PubChem CID 124886 (glutathione)

Where Glutathione Comes From and How It Works

Origin and discovery

Glutathione (GSH) is not a synthetic compound created in a laboratory. It is produced continuously inside every nucleated cell in the human body through a two-step enzymatic process driven by the enzymes glutamate-cysteine ligase (GCL) and glutathione synthase. The tripeptide was first isolated by Hopkins in 1921 and structurally characterized over the following decades. Its role as the primary cellular redox buffer was established through the mid-twentieth century as researchers mapped the enzymes that govern its recycling and conjugation functions. Unlike most antioxidants consumed in the diet, glutathione operates predominantly inside cells rather than in circulation, which is a distinction with significant implications for supplementation strategy.

The GSH/GSSG redox cycle

Glutathione cycles between its reduced form (GSH) and its oxidized form (GSSG). When GSH neutralizes a reactive oxygen species (ROS), it donates an electron and becomes GSSG. The enzyme glutathione reductase (GSR) then uses NADPH to regenerate GSH from GSSG, completing the redox cycle. A 2023 comprehensive review by Ferguson and Bridge in Ageing Research Reviews describes this cycle in detail and documents its decline with aging, noting that the GSH:GSSG ratio serves as a sensitive index of oxidative stress in tissues. Glutathione peroxidases (GPx) and glutathione S-transferases (GST) extend this system by reducing hydrogen peroxide and conjugating toxins for export, respectively. The result is a coordinated intracellular defense network that no single downstream antioxidant can replicate.

Cellular compartmentalization and mitochondrial pools

Glutathione is not distributed uniformly across the cell. The cytoplasmic pool is the largest, but mitochondrial glutathione deserves particular attention because mitochondria lack the machinery to synthesize GSH directly and must import it from the cytoplasm via specific transporters. A 2024 review by Checa-Ros and colleagues in International Journal of Molecular Sciences details how mitochondrial GSH depletion is implicated in the oxidative damage underlying age-related disease. Because mitochondrial GSH is a separate compartment from cytoplasmic GSH, supplementation strategies that raise systemic levels may not fully replenish the mitochondrial pool, an important caveat when evaluating efficacy claims.

Phase II liver detoxification and conjugation

Hepatic glutathione is central to Phase II detoxification. Glutathione S-transferases conjugate electrophilic compounds, including metabolites of drugs, environmental pollutants, and oxidized lipids, to the GSH molecule, creating water-soluble conjugates that are excreted via bile or urine. This process renders potentially reactive compounds inert. The liver maintains the highest tissue concentrations of glutathione in the body, reflecting this conjugation demand. The Superpower guide to detoxification and liver function biomarkers describes how several liver enzymes, including gamma-glutamyl transferase (GGT), are mechanistically linked to glutathione metabolism and can serve as indirect reflections of hepatic GSH activity.

How Glutathione Levels Change With Age and Disease

Age-related GSH depletion

Endogenous glutathione synthesis declines with age. A landmark 2011 study by Sekhar and colleagues in the American Journal of Clinical Nutrition used stable-isotope [2H2]glycine infusions in 8 elderly and 8 younger subjects and demonstrated that older adults had significantly deficient red-blood-cell GSH synthesis rates and concentrations versus young adults, and that two weeks of dietary supplementation with the precursor amino acids cysteine and glycine fully restored GSH synthesis and concentrations and lowered plasma oxidative stress and oxidant damage markers — indicating that the bottleneck is substrate availability, not enzymatic failure. This finding reframed the aging-GSH relationship: the bottleneck is not the synthesis machinery itself but the substrate supply, which has practical implications for supplementation strategy.

Glutathione as a disease biomarker

Low GSH and elevated oxidative stress markers have been documented across a wide range of conditions. A 2018 review by Ballatori and colleagues in Advances in Clinical Chemistry synthesizes evidence linking impaired GSH status to cardiovascular disease, neurodegenerative disease, liver disease, and metabolic dysfunction. A 2020 review by Bjørklund and colleagues in Free Radical Biology and Medicine documented glutathione redox imbalance across multiple studies of autism spectrum disorder, and a 2021 meta-analysis by Liu and colleagues in Translational Psychiatry analyzed 87 studies (n = 9,109) and found reduced GSH and elevated oxidative stress markers in children with ASD compared to controls. These associations are not proof of causality, but they establish GSH status as a meaningful correlate of systemic oxidative burden.

The measurement problem

Interpreting glutathione data requires understanding its measurement limitations. A critical 2017 review by Giustarini and colleagues in Antioxidants and Redox Signaling documents the technical challenges: plasma GSH is present at very low concentrations and is highly susceptible to pre-analytical degradation from improper blood handling, temperature changes, and sample processing delays. Most of what appears as "plasma GSH" in studies reflects erythrocyte GSH that leaked during processing. Whole-blood or red blood cell GSH measurements are more representative. This matters when evaluating supplement studies: the assay used, sample handling protocol, and whether whole-blood or plasma was measured all affect the validity of results.

Delivery Forms: What the Evidence Shows

Oral glutathione: Can it raise body stores?

For years, oral glutathione was considered minimally bioavailable because the gastrointestinal tract was assumed to hydrolyze it into constituent amino acids before absorption. The landmark rebuttal came from a 2015 randomized controlled trial by Richie and colleagues in the European Journal of Nutrition. In this trial, 54 non-smoking adults received oral glutathione at 250 mg/day or 1,000 mg/day versus placebo for 6 months with a 1-month washout. Blood and tissue GSH stores increased in a dose- and time-dependent manner: the high-dose group showed approximately 30–35% increases across erythrocytes, plasma, and lymphocytes and a 260% increase in buccal cell GSH at 6 months, while the low-dose group showed 17–29% increases across blood compartments versus placebo (p < 0.05). Natural killer cell cytotoxicity more than doubled in the high-dose group versus placebo at 3 months (p < 0.05), and values returned to baseline after washout. This trial established that long-term oral supplementation does raise body GSH stores, resolving the earlier debate about bioavailability, though the mechanism of absorption (intact peptide vs. amino acid recycling) remains under investigation. A separate 2020 double-blind randomized controlled trial by Lai and colleagues in Nutrients randomized 61 patients with liver cirrhosis to oral glutathione 500 mg/day, vitamin B6, or placebo for 12 weeks with extended follow-up over a median of 984 days, and found that neither vitamin B6 nor GSH supplementation produced statistically significant effects on oxidative stress or antioxidant capacity indicators during the intervention period — though baseline GSH status (higher GSH, higher GSH:GSSG ratio, higher GSH-S-transferase activity) was independently associated with lower disease severity. The null intervention result tempers enthusiasm for short-term oral GSH as a therapeutic in advanced liver disease and underscores that bioavailability alone does not guarantee clinical benefit in populations with significant hepatic dysfunction.

Liposomal glutathione

Liposomal encapsulation wraps glutathione in a lipid bilayer to protect it from gastrointestinal degradation and facilitate cellular uptake. A 2018 trial by Sinha and colleagues in the European Journal of Clinical Nutrition administered liposomal GSH at 500 mg and 1,000 mg daily to 12 healthy adults and reported that whole blood GSH rose by approximately 40%, erythrocyte GSH by 25%, plasma GSH by 28%, and peripheral blood mononuclear cell GSH by 100% after two weeks, with natural killer cell cytotoxicity increasing by up to 400% and lymphocyte proliferation by up to 60%. The very small cohort (n = 12) and short four-week duration limit the strength of the finding, but the magnitudes support the rationale for liposomal encapsulation as a potentially more efficient delivery strategy than standard oral capsules.

Sublingual and buccal delivery

Absorption across the oral mucosa bypasses first-pass hepatic metabolism. A 2019 pilot study by Schmitt and colleagues in PLoS ONE tested a nano-sized orobuccal glutathione formulation in healthy volunteers and reported measurable increases in plasma GSH parameters. The sample was small and the study design exploratory, but the finding supports the concept that sublingual delivery merits further investigation as a route that circumvents GI hydrolysis.

Intravenous glutathione

Intravenous delivery bypasses gastrointestinal and hepatic barriers entirely, delivering reduced glutathione directly into systemic circulation. IV glutathione has been investigated in the context of Parkinson's disease, where a proposed mechanism involves protecting dopaminergic neurons from oxidative damage. A 2009 randomized double-blind pilot trial by Hauser and colleagues in Movement Disorders randomized 21 Parkinson's patients (11 glutathione, 10 placebo) to IV glutathione 1,400 mg or placebo three times weekly for 4 weeks and found no statistically significant benefit on UPDRS ADL + motor scores (mean 2.8 units greater improvement on glutathione during treatment, p = 0.32; mean 3.5 units greater worsening during the subsequent 8-week follow-up, p = 0.54), with similar adverse-event rates between groups. Intranasal glutathione, which delivers GSH to the olfactory bulb and bypasses the blood-brain barrier, has been explored in a series of trials by Mischley and colleagues. A 2015 Phase I/IIa randomized double-blind controlled trial in Movement Disorders enrolled 30 patients with Parkinson's disease randomized to 300 mg/day or 600 mg/day intranasal glutathione in three divided doses versus saline placebo for 3 months with a 1-month washout, and found that all groups met tolerability criteria with no substantial between-group differences in adverse events — a safety/tolerability signal rather than an efficacy demonstration. A 2017 Phase IIb double-blind placebo-controlled trial in the Journal of Parkinson's Disease randomized 45 patients with Hoehn & Yahr stage 1-3 Parkinson's to placebo, 100 mg, or 200 mg intranasal glutathione three times daily for 3 months with 1-month washout; the 200 mg arm showed within-group UPDRS total improvement of -4.6 points (SD 4.7; p = 0.0025) and motor subscore improvement of -2.2 (SD 3.8; p = 0.0485), but neither active arm was superior to placebo on between-group comparison — a finding that illustrates how placebo response in Parkinson's trials can obscure within-group signals. A 2016 study in NPJ Parkinson's Disease demonstrated CNS uptake of intranasal glutathione in patients. A 2024 review by Dominari and colleagues in Nutrients summarizes the mechanistic rationale for nebulized GSH in neurodegenerative disease. A 2022 open-label cross-over trial by Marianetti and colleagues in Alzheimer's and Dementia: Translational Research and Clinical Interventions administered oleuropein (an olive polyphenol) combined with S-acetyl glutathione as a dietary supplement for 6 months to 18 patients with mild Alzheimer's disease and reported that neurocognitive parameters stabilized or improved across the cohort on neuropsychological testing, with the small sample and absence of a placebo arm limiting strength of inference. Across these programs, the studies are preliminary; they establish feasibility and safety signals rather than clinical efficacy. No IV glutathione product is FDA-approved for any indication.

Inhaled glutathione

Inhaled glutathione has been studied in cystic fibrosis, where lung fluid GSH concentrations are substantially lower than in healthy airways. The evidence from large randomized trials has been largely negative. A 2013 randomized double-blind placebo-controlled trial by Griese and colleagues in the American Journal of Respiratory and Critical Care Medicine randomized 153 cystic fibrosis patients (73 glutathione, 80 placebo) to inhaled glutathione 646 mg via eFlow nebulizer every 12 hours versus placebo for 6 months and found no statistically significant benefit on the primary FEV1 endpoint (pre-post difference p = 0.180; area-under-curve p = 0.205), with similar adverse-event rates between groups. A 2015 single-blind randomized controlled trial by Calabrese and colleagues in the Journal of Cystic Fibrosis enrolled 105 cystic fibrosis patients (54 adults, 51 pediatric) over 12 months of inhaled glutathione versus control and did not achieve its pre-specified primary outcome of 15% improvement in FEV1% predicted, though a subgroup with moderate lung disease showed signals of benefit at interim timepoints — findings that do not support routine use but leave the door open for subpopulation investigation. Earlier pilot studies, including a 2004 study by Hartl and colleagues in the American Journal of Respiratory and Critical Care Medicine and a 2005 study by Bishop and colleagues in Chest, had suggested improvements in alveolar GSH and lung function; the larger trials did not confirm these signals. The cystic fibrosis data illustrates the gap between biochemical plausibility and clinical efficacy.

GlyNAC: The Precursor Strategy

Why precursors may outperform direct supplementation

Because GSH synthesis in aging is bottlenecked by cysteine and glycine availability rather than by enzyme function, supplementing with the precursor amino acids rather than with glutathione itself is a mechanistically coherent strategy. GlyNAC combines glycine (Gly) with N-acetylcysteine (NAC), which provides the cysteine substrate after intracellular deacetylation. NAC's role as a cysteine donor was established in a foundational 2014 review by Rushworth and Megson in Pharmacology and Therapeutics, which confirmed that NAC's antioxidant activity depends on intracellular conversion to cysteine and subsequent GSH synthesis rather than on any direct antioxidant activity of NAC itself.

Human trial evidence for GlyNAC

Two randomized trials by Kumar and colleagues provide the most rigorous clinical evidence for the GlyNAC approach. A 2021 open-label pilot trial by Kumar and colleagues in Clinical and Translational Medicine enrolled 16 older adults (ages 70-80) and 8 young-adult reference subjects and administered GlyNAC for 24 weeks followed by a 12-week withdrawal period, reporting that supplementation corrected red-blood-cell GSH deficiency and improved oxidative stress, mitochondrial dysfunction, inflammation, endothelial dysfunction, insulin resistance, genomic stability, cognition, muscle strength, gait speed, body fat, and waist circumference — with benefits declining after GlyNAC was withdrawn. The open-label design and small cohort limit inference, but the breadth of domains improved motivated the subsequent placebo-controlled 2022 trial. A larger 2022 placebo-controlled randomized trial by Kumar and colleagues in the Journals of Gerontology: Series A randomized 24 older adults (mean age 70–80 years) 1:1 to GlyNAC or isonitrogenous alanine placebo for 16 weeks and found that erythrocyte glutathione concentrations were severely deficient at baseline in older versus young reference adults, improved rapidly within two weeks of GlyNAC supplementation, and were corrected to young-adult levels by 16 weeks, with concurrent improvements in oxidative stress markers, mitochondrial dysfunction, inflammation, physical function, muscle strength, and multiple aging hallmarks. The relatively small cohort means longer-term safety and efficacy data in larger populations are still needed. These trials are notable for their mechanistic coherence: they intervene specifically at the substrate-supply bottleneck identified in the 2011 Sekhar study and measure outcomes directly relevant to the proposed mechanism.

Dietary phytonutrients that support endogenous GSH

Endogenous GSH synthesis can also be supported by dietary compounds that upregulate the NRF2 transcription factor, which governs expression of GCL and other antioxidant enzymes. A 2019 review by Minich and Brown in Nutrients synthesizes evidence for sulforaphane (from cruciferous vegetables), curcumin, selenium, and other phytonutrients as NRF2 activators that may support endogenous GSH levels. These food-derived compounds do not provide glutathione directly; they modulate the gene expression programs that control how much the body synthesizes.

Glutathione and Skin Lightening: Evidence and Controversy

The proposed mechanism

Glutathione's proposed role in skin lightening derives from its inhibition of tyrosinase, a rate-limiting enzyme in melanin synthesis. By scavenging copper ions required by tyrosinase and shifting melanin production from dark eumelanin toward lighter phaeomelanin, elevated GSH levels may reduce pigmentation. This mechanism is biologically plausible and has been explored extensively in Asian markets, where oral and IV glutathione has been widely used for skin brightening purposes despite limited regulatory approval for this indication.

What the randomized trials show

A widely cited 2016 review by Sonthalia and colleagues in the Indian Journal of Dermatology, Venereology and Leprology evaluated the evidence base and safety concerns, including the Philippines FDA's 2011 advisory warning against IV glutathione for skin whitening. A 2020 systematic review by Sitohang and Ninditya in Dermatology Research and Practice analyzed three randomized controlled trials and concluded that glutathione "is not beneficial enough as a skin-whitening agent as it was only effective in some parts of the body and did not elicit long-lasting effects," with oral preparations tolerated but parenteral forms raising safety concerns. A 2025 systematic review by Sarkar, Yadav, and colleagues in the International Journal of Dermatology characterized topical (0.5%) and oral (250–500 mg/day) glutathione as moderately effective for skin lightening while explicitly stating that intravenous glutathione is contraindicated due to lack of efficacy and adverse side effects, citing a single placebo-controlled IV study with marginal results (37.5% vs. 18.7%, p = 0.054).

Small randomized trials have produced mixed signals. A 2012 RCT by Arjinpathana and Asawanonda in the Journal of Dermatological Treatment reported modest skin-lightening effects with oral glutathione. A 2016 open-label single-arm trial by Handog and colleagues in the International Journal of Dermatology administered an oral glutathione lozenge daily for 8 weeks to 30 Filipino women and reported significant decreases in melanin indices from baseline, evident as early as 2 weeks, with no serious adverse events or abnormal laboratory findings — though the open-label single-arm design without a placebo comparator limits causal inference. A 2021 double-blind RCT by Weschawalit and colleagues in the International Journal of Dermatology combining topical and oral glutathione in a Thai cohort found statistically significant but modest whitening effects, and a 2014 randomized double-blind matched-pair placebo-controlled trial by Watanabe and colleagues in Clinical, Cosmetic and Investigational Dermatology applied 2% oxidized glutathione (GSSG) lotion twice daily to one facial side versus placebo on the other in 30 healthy adult women over 10 weeks, reporting a statistically significant reduction in melanin index on the GSSG side at 10 weeks (p < 0.001), along with improvements in moisture, wrinkle depth, and smoothness in the latter half of the study. Across these trials, effect sizes are modest, follow-up periods short, and sample sizes small. The aggregate evidence does not support strong efficacy claims, and IV use specifically carries unresolved safety concerns around renal toxicity with high-dose chronic administration. The Superpower educational guide on glutathione and skin tone covers the skin-lightening mechanism and evidence in more detail.

Regulatory and Legal Status

FDA classification

As of April 2026, oral glutathione is regulated as a dietary supplement in the United States under the Dietary Supplement Health and Education Act (DSHEA) of 1994. It is not FDA-approved as a drug for any indication. Intravenous or compounded glutathione formulations are subject to Section 503A compounding pharmacy regulations and require a patient-specific prescription from a licensed provider. IV glutathione is not classified as a Category 2 or Category 3 bulk drug substance under FDA's compounding framework, meaning it is not explicitly prohibited in 503A compounding as of April 2026, but it has no FDA-approved indication and is not an FDA-approved drug product. Any claims made by supplement manufacturers about glutathione's effects on disease are subject to FTC substantiation standards.

Philippines FDA and IV safety concerns

The Philippines Food and Drug Administration issued an advisory in 2011 warning against the use of IV glutathione for skin whitening, citing an absence of evidence for efficacy by this route and safety concerns including renal toxicity with high-dose chronic administration, Stevens-Johnson syndrome, and potential nerve damage. While this advisory does not govern US practice, it reflects the regulatory concern about extrapolating supplement biology to IV administration and about the absence of controlled safety data for the skin-whitening indication specifically.

What this means practically

Oral glutathione supplements are widely available over the counter. IV glutathione is available through compounding pharmacies by prescription but lacks FDA approval or robust clinical efficacy data for any indication. Products marketed online as "glutathione injections" or "whitening drips" that bypass medical oversight are unregulated and carry uncharacterized contamination and dosing risks. Superpower does not offer or facilitate access to IV or compounded glutathione.

Glutathione vs. NAC vs. GlyNAC: Key Differences

Direct glutathione supplementation, N-acetylcysteine (NAC), and the GlyNAC combination are often discussed as interchangeable interventions, but they differ in mechanism, evidence base, and clinical context.

Oral glutathione delivers the intact tripeptide; whether it is absorbed intact or hydrolyzed and reassembled is still being investigated, but the 2015 Richie RCT established that body stores do rise with sustained supplementation. NAC does not provide glutathione directly. As the Rushworth and Megson review established, NAC must be deacetylated intracellularly to release cysteine, which then drives GSH synthesis. NAC's antioxidant effect is mediated through this GSH-synthesis route rather than through any direct action. GlyNAC addresses both of the rate-limiting substrates simultaneously (cysteine via NAC and glycine directly), which is the mechanistically most complete approach to correcting age-related GSH deficiency. The 2022 Kumar trial documented GlyNAC's ability to correct multiple aging-related hallmarks that NAC or glycine alone did not fully address in the same population. For practical context on the NAC pathway and how it relates to glutathione, the Superpower guide comparing NAC and glutathione covers the distinctions in accessible detail.

This comparison is for scientific context only. These interventions have different regulatory statuses: oral glutathione and NAC are dietary supplements; prescription NAC formulations exist for clinical indications unrelated to antioxidant supplementation. None are FDA-approved for oxidative stress or skin lightening indications.

Safety: What Is and Is Not Known

Oral safety profile

Oral glutathione supplementation at doses studied in published RCTs (250–1,000 mg/day) appears well tolerated over periods up to six months. The 2015 Richie trial did not report significant adverse events. Long-term safety data beyond six months in healthy populations is limited. Gastrointestinal discomfort has been noted anecdotally at higher doses. Because glutathione is an endogenous molecule and the supplementation doses studied are modest relative to tissue concentrations, the theoretical safety concern is low, but formal long-term safety studies have not been conducted.

IV glutathione safety concerns

IV administration bypasses the body's normal absorption controls and delivers high concentrations of glutathione directly into systemic circulation. The safety concerns associated with high-dose IV glutathione for skin whitening — including renal toxicity, neurological effects, and Stevens-Johnson syndrome — are documented in the dermatology literature and prompted the Philippines FDA advisory. These risks are specifically associated with chronic, high-dose IV administration in non-clinical settings. Lower-dose IV use in monitored clinical settings has a different risk profile, but no safety data from controlled trials is available to characterize it systematically.

Risks from unregulated products

Products sold online as glutathione injections, whitening drips, or "push" formulations outside of licensed pharmacy and clinical oversight are unregulated. Independent testing of similar peptide and supplement injectables has documented contamination with endotoxins, bacteria, and incorrect compounds. There is no quality assurance pathway for these products.

Who Should Approach Glutathione Supplementation Cautiously

Based on glutathione's proposed mechanisms and the available evidence, the following groups face elevated theoretical risk or should consult a provider before supplementing.

• Individuals with active cancer or a history of cancer — glutathione's cytoprotective role in cells is not tumor-selective; elevated intracellular GSH in cancer cells has been associated with resistance to chemotherapy, and supplementation during active cancer treatment should only occur under oncology guidance.
• Individuals with renal impairment — high-dose IV glutathione has been associated with renal toxicity in the dermatology literature; those with compromised kidney function should not use IV formulations without nephrology oversight.
• Individuals taking medications whose efficacy depends on cellular oxidative stress — certain chemotherapy agents and some antimicrobial drugs rely on ROS-generating mechanisms; antioxidant supplementation during these therapies may affect drug efficacy. This should be discussed with the prescribing provider.
• Pregnant and breastfeeding individuals — no safety data exists for glutathione supplementation in pregnancy or lactation; general supplement caution applies.

Which Biomarkers Are Relevant if You Are Exploring Glutathione and Oxidative Stress?

Glutathione itself is not routinely measured on standard blood panels, but several markers reflect the biological processes it governs. Understanding these markers provides meaningful context for anyone evaluating their oxidative burden, liver detoxification capacity, or inflammatory status.

• Gamma-Glutamyl Transferase (GGT): GGT catalyzes the extracellular degradation of glutathione and is the primary enzyme that salvages cysteine from circulating GSH. Elevated GGT is associated with hepatic oxidative stress, alcohol metabolism burden, and reduced GSH recycling efficiency. The Superpower guide to GGT covers its interpretation in detail. GGT is included in the standard liver enzyme panel available through Superpower's testing.
• High-Sensitivity CRP (hs-CRP): Systemic inflammation and oxidative stress are interlinked; elevated hs-CRP reflects an inflammatory environment in which ROS generation is increased and antioxidant demand is elevated. Tracking hs-CRP provides an indirect signal of oxidative burden. The Superpower guide on inflammation biomarkers covers hs-CRP alongside other inflammatory markers.
• Homocysteine: The transsulfuration pathway converts homocysteine to cystathionine and ultimately to cysteine, the rate-limiting precursor for glutathione synthesis. Elevated homocysteine may reflect impaired transsulfuration and reduced cysteine availability for GSH production. Homocysteine is included in Superpower's Methylation Panel and is also relevant to cardiovascular risk.
• ALT and AST: Alanine aminotransferase and aspartate aminotransferase reflect hepatocyte integrity. Because the liver is the primary site of glutathione synthesis and Phase II conjugation, elevated liver enzymes can signal conditions in which hepatic GSH demand is high or hepatocyte turnover is increased. The Superpower blog on optimal liver enzyme ranges provides evidence-based context for interpreting these values.
• GGT/ALT Ratio: This ratio is used as a marker of hepatic oxidative stress distinct from hepatocellular injury. The Superpower GGT/ALT guide covers its clinical interpretation.
• Ferritin: Ferritin is an acute-phase reactant and a marker of iron storage, but elevated ferritin in the absence of iron overload can reflect systemic oxidative stress and inflammation. Iron in its free form catalyzes the Fenton reaction, generating hydroxyl radicals that deplete GSH. Tracking ferritin alongside inflammatory markers provides a more complete picture of oxidative burden.
• Vitamin C: Ascorbate and glutathione are interconnected in the antioxidant network: vitamin C can regenerate oxidized glutathione and serves as a co-antioxidant that spares GSH. Vitamin C deficiency increases GSH depletion rate. Superpower's Nutrients and Vitamins panel measures vitamin C directly.
• Complete Metabolic Panel (CMP): Creatinine, BUN, albumin, and liver enzymes together assess the organ systems most dependent on glutathione for functional integrity: the liver (synthesis and conjugation), kidney (excretion of GSH conjugates), and overall protein status (albumin reflects synthetic capacity).

A fuller overview of the liver-relevant markers in this list appears in the Superpower guide to detoxification and liver function biomarkers.

When to Take This Seriously

If you are exploring glutathione because of persistent fatigue, slow recovery, skin concerns, or a general interest in supporting your antioxidant biology as you age, these are real and reasonable motivations. Established clinical pathways exist for several conditions linked to low GSH status: metabolic dysfunction, liver disease, and cardiovascular risk all have well-characterized evaluation and management approaches through primary care and specialist medicine. If symptoms are significant or unexplained, the first step is clinical evaluation, not supplementation. Understanding your baseline oxidative, hepatic, and inflammatory markers through bloodwork provides objective context for any subsequent intervention, whether dietary, supplemental, or medical.

That commitment to measuring before acting is central to how Superpower approaches preventive health. Superpower's approach to preventive health is grounded in the belief that understanding your biology is the foundation for every health decision. For glutathione specifically, the biomarkers described above translate the complexity of intracellular redox biology into measurable signals that inform rather than replace clinical judgment.

IMPORTANT SAFETY INFORMATION

Glutathione is not FDA-approved as a drug for any indication. Oral glutathione is a dietary supplement regulated under DSHEA; its effects have not been evaluated by the FDA. Intravenous (IV) and compounded glutathione formulations are not FDA-approved drugs. Any compounded glutathione product is dispensed only pursuant to a patient-specific prescription from a licensed provider and should not be obtained from non-medical sources. Superpower Health does not prescribe, sell, compound, or facilitate access to IV or compounded glutathione.

Warnings: IV glutathione for skin whitening has been associated with renal toxicity, Stevens-Johnson syndrome, and neurological effects in case reports and prompted a Philippines FDA advisory. Do not use IV glutathione outside of licensed clinical and pharmacy oversight. Individuals with cancer should consult their oncology team before supplementing with antioxidants, as elevated intracellular GSH may affect chemotherapy efficacy. Individuals with renal impairment should avoid high-dose IV formulations. Supplement–drug interactions are possible for medications that rely on oxidative mechanisms for efficacy.

Contraindications and cautions: active cancer under chemotherapy without oncology guidance; renal impairment with IV use; pregnancy and breastfeeding (insufficient safety data); use of medications whose mechanism depends on cellular oxidative stress.

Common reported effects with oral supplementation: generally well tolerated at studied doses (250–1,000 mg/day); gastrointestinal discomfort reported at higher doses in some individuals; long-term safety data beyond six months is limited.

As of April 2026, glutathione is not classified as a prohibited Category 2 or Category 3 bulk drug substance under the FDA compounding framework. This classification is subject to change; consult current FDA guidance before initiating compounded glutathione therapy.

Additional Questions

Is glutathione for skin whitening safe and effective?

The evidence base is limited and contested. Small RCTs have found modest skin-lightening effects with oral and topical glutathione, but effect sizes are small, trials are short, and independent replication is limited. IV glutathione for skin whitening has been the subject of explicit safety warnings from the Philippines FDA, citing renal toxicity risk and absence of efficacy evidence for this route and indication. Regulatory bodies including dermatology societies do not currently endorse systemic glutathione as a standard skin-lightening treatment. The Superpower guide to glutathione and skin tone covers the evidence in detail.

What is the 2026 FDA peptide classification for glutathione?

As of April 2026, glutathione is not classified as a Category 2 or Category 3 bulk drug substance under the FDA's compounding framework. The February 2026 FDA reclassification that affected certain other peptides (including several GHRH analogs and other compounds) did not directly reclassify glutathione. Glutathione remains eligible for 503A compounding by a licensed pharmacy pursuant to a patient-specific prescription, with the important caveat that it has no FDA-approved drug indication.

Are there biomarkers that reflect glutathione status?

Direct measurement of whole-blood or erythrocyte glutathione is available through specialty laboratories but is not a routine component of standard panels. Indirect biomarkers that reflect the processes glutathione governs include GGT (liver GSH recycling and oxidative burden), hs-CRP (systemic inflammatory and oxidative stress environment), homocysteine (transsulfuration pathway efficiency, a rate-limiting step for cysteine supply), and liver enzymes ALT and AST. These markers together provide a functional picture of oxidative and hepatic burden without requiring direct GSH measurement.